Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

3D Printed Kidney Phantoms Aid Nuclear Medicine Dosing Calibration

By Society of Nuclear Medicine | December 8, 2016

This is a photograph of smallest to largest: newborn, 1-y-old, 5-y-old, and adult. Source: University of Wurzburg

In nuclear medicine, the goal is to keep radiation exposure at a minimum, while obtaining quality images. Optimal dosing for individual patients can be difficult to determine. That’s where 3D-printed organ models of varying size and shape could be of great use.

In a study reported in the December issue of The Journal of Nuclear Medicine, researchers at the University of Würzburg in Würzburg, Germany, demonstrated that low-cost 3D printing technology can be used for clinical prototyping. Johannes Tran-Gia, PhD, the study’s corresponding author, explains: “This research shows a way of producing inexpensive models of patient-specific organs/lesions for providing direct and patient-specific calibration constants. This is particularly important for imaging systems suffering from poor spatial resolution and ill-defined quantification, such as SPECT/CT.”

To demonstrate the potential of 3D printing techniques for quantitative SPECT/CT imaging, kidneys–as organs-at-risk in many radionuclide therapies–were selected for the study.

A set of four one-compartment kidney dosimetry phantoms and their spherical counterparts with filling volumes between 8 mL (newborn) and 123 mL (adult) were designed based on the outer kidney dimensions provided by Medical Internal Radiation Dose (MIRD) guidelines. Based on these designs, refillable, waterproof and chemically stable models were manufactured with a fused deposition modeling 3D printer. Nuclide-dependent SPECT/CT calibration factors for technetium-99m (Tc-99m), lutetium-177 (Lu-177), and iodine-131 (I-131) were then determined to assess the accuracy of quantitative imaging for internal renal dosimetry.

Tran-Gia notes, “Although in our study the kidneys were modeled as a relatively simple one-compartment model, the study represents an important step towards a reliable determination of absorbed doses and, therefore, an individualized patient dosimetry of other critical organs in addition to kidneys.”

Ultimately, affordable 3D printing techniques hold the potential for manufacturing individualized anthropomorphic phantoms in many nuclear medicine clinical applications.


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE